Description
HRYZ-T101 is an experimental treatment currently being studied in clinical trials. It is a type of immunotherapy called a TCR-T cell therapy. This therapy involves modifying a patient's own T cells (a type of immune cell) to better recognize and attack cancer cells. Specifically, HRYZ-T101 is being investigated for solid tumors that test positive for Human Papillomavirus type 18 (HPV18). The goal of the ongoing Phase 1 trial is to determine the safest dose (RP2D) and see if HRYZ-T101 is safe and shows early signs of effectiveness in patients with these types of tumors. It is important to note that this treatment is still in early stages of development and is not yet approved for use in colorectal cancer or any other cancer.
Mechanism of Action
HRYZ-T101 is a T-cell receptor (TCR)-T cell therapy. This means that T cells are taken from a patient's blood and genetically engineered in a lab to express a specific T-cell receptor (TCR). This engineered TCR is designed to recognize a specific target found on cancer cells, particularly those associated with HPV18 positive tumors. Once infused back into the patient, these modified T cells (TCR-T cells) are intended to find and destroy the cancer cells expressing that target.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.